We showed that hepatic Chrebpa is reduced in several mouse liver fibrosis (CCl4, TAA, and BDL) models and human liver fibrosis due to HBV, NASH, alcohol liver disease, and primary biliary cholangitis.[15, 16, 17, 18] We also identified Chrebpα as a previously unknown downstream target of TGFβ signaling in hepatocytes. The gene discussed is TGFB1; the disease is Hepatic fibrosis.